pharmaphorum
FEBRUARY 10, 2021
Improving the Safety, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need. This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.
Outsourcing Pharma
FEBRUARY 9, 2021
The federal agency continues to keep researchers, pharma firms and citizens apprised of current happenings and research related to the virus and pandemic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
FEBRUARY 12, 2021
The Walden Group is pleased to announce the appointment of Dennis Spamer (38) as member of the Board authorized to sign as statutory director of the company. Together with Thomas Creuzberger, who has been managing Movianto Germany since more than 20 years and Stéphane Baudry, founder and CEO of the Walden Group, Spamer shall push on the further development of the logistics specialist.
Druggist
FEBRUARY 10, 2021
Statins, also known as lipid-lowering drugs, are a popular class of drugs prescribed in the UK. When looking at the most popular drugs in the UK , atorvastatin was the most prescribed drug. Simvastatin also made to the top of most commonly prescribed drugs. Historically, statins have been subject to scrutiny from the press, mostly picking on a negative aspect of stain treatment.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
FEBRUARY 11, 2021
Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . ACI-35.030, partnered with Johnson & Johnson, is designed to stimulate the body to generate antibodies against tau protein, one of the factors though to play a role in the development of AD dementia.
Outsourcing Pharma
FEBRUARY 10, 2021
This monthâs announcements about industry hires, promotions, alliances and other important events includes Merck, Lonza, Medable and other key firms.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Marketing Network
FEBRUARY 10, 2021
Discover the AI methods & tools set to revolutionize healthcare, medicine & diagnostics, as well as industry applications and key insights at our AI in Healthcare Virtual Summit. This is a 2 in 1 online summit about the advancements and implementations of healthcare in AI. Hear from industry lead experts, connect with healthcare professionals, enjoy interactive Q&A discussions, and much more.
pharmaphorum
FEBRUARY 12, 2021
The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. Rory Mullen, head of biopharma at Ireland’s economic development agency IDA Ireland tells pharmaphorum why business is blossoming in the Emerald Isle. With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle.
Outsourcing Pharma
FEBRUARY 9, 2021
The collaboration between the Jameel Clinic and pharma firm will harness artificial intelligence and machine learning in developing health solutions.
That Frugal Pharmacist
FEBRUARY 6, 2021
Asking yourself how much rent you can afford is the first step when you plan to find a new home. Answering this question can be the starting point to deciding where you want to live and what kind of place you want to rent. Key point: this information is for general use purposes. If you … How Much Rent Can I Afford in 2021? Read More ».
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Med Ed 101
FEBRUARY 10, 2021
Cyclobenzaprine (podcast episode) is a skeletal muscle relaxant that is most commonly used for muscle spasms and back pain. It definitely has some potential adverse effects that I have seen lead to the prescribing cascade. Here’s a rundown of medications that may help you recognize cyclobenzaprine and the prescribing cascade. Dry Mouth Some of the […].
pharmaphorum
FEBRUARY 9, 2021
The UK government’s massive spending on the coronavirus pandemic response has been “rife with conflicts of interest”, says the opposition Labour Party, and an independent watchdog should be set up to oversee procurement contracts. That was the message delivered by shadow Cabinet Office minister Rachel Reeves in a speech yesterday which claimed almost £2 billion of the £23.1 billion public sector spend on the pandemic went on contracts that were awarded to “Conservative friends and donors”
Outsourcing Pharma
FEBRUARY 11, 2021
The global professional services firm has signed on the newest partner in the collaboration, aimed toward promoting innovation in pharma manufacturing.
That Frugal Pharmacist
FEBRUARY 7, 2021
I’m swamped. That’s how it feels at least. Trying to do a quick little blog check in here about some of the things I am thinking and feeling as I progress on the road to freelance income. I can’t decide if I have taken on too many things or if this is just a season … February Ramblings – Cautionary Insights on the Road to Freelance Read More ».
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Med Ed 101
FEBRUARY 7, 2021
Here’s a list of some of the most common CYP2C19 drug interactions that I have seen in clinical practice. Citalopram and Omeprazole Interaction Omeprazole can significantly increase the concentration of citalopram. Because of this drug interaction, there is a greater risk for citalopram toxicity and QTc prolongation. Omeprazole inhibits CYP2C19 which is an important breakdown […].
pharmaphorum
FEBRUARY 11, 2021
Rob Wood has acquired a large minority stake in performance-io through a multimillion-pound deal that will see him join the specialist online performance marketing agency’s executive board. A former AstraZeneca director, Wood founded commercial and medical benchmarking firm STEM in 2007 before selling it to UDG Healthcare for £84 million in 2016. Since leaving that company he has invested in a number of disruptive technology-driven pharma service providers. performance-io ’s founder and CEO Matt
Outsourcing Pharma
FEBRUARY 11, 2021
Immunai has secured a total of $80m in funding to develop and promote its efforts to harness machine learning to fuel advancement of novel immunotherapies.
Pharma Times
FEBRUARY 10, 2021
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
pharmaphorum
FEBRUARY 12, 2021
Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin franchise. . The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.
pharmaphorum
FEBRUARY 10, 2021
Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to take stock and prioritise. Compliance managers have less than six months to rewrite processes and procedures in line with the updated ABPI code of practice before it becomes enforceable in July. But it doesn’t all have to be done at once, says Dr Rina Newton, managing director at code consultancy firm, CompliMed.
pharmaphorum
FEBRUARY 8, 2021
Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma. The green light comes too late for holders of the contingent value right (CVR) BMS offered as a sweetener to its takeover of Celgene, which lapsed because liso-cel didn’t get approval by the deadline of 31 December.
pharmaphorum
FEBRUARY 12, 2021
Injected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get the attention it needs. Ipsen’s John Chaddock tells us why the company is investing heavily in neurotoxin research and how he hopes to raise awareness among young scientists and the NHS. When the COVID-19 pandemic first hit, countries were forced to make difficult decisions about which healthcare services to continue and which to halt as systems came under immense st
pharmaphorum
FEBRUARY 8, 2021
In the third part of this series taking stock of t he 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third VPAS objective that relates to the economy and innovation. The objectives for the economy and innovation are to: deliver a net benefit to the UK economy overall; and. support the life sciences industry across the UK and future innovation.
pharmaphorum
FEBRUARY 11, 2021
Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. Patient engagement can help address long-running industry issues, such as recruitment and retention, as well as reducing the need for additional trial protocol amendments.
pharmaphorum
FEBRUARY 11, 2021
The generic respiratory drug budesonide could be an option to treat COVID-19, a small scale clinical study has suggested. Marketed in the past by AstraZeneca as Pulmicort, budesonide is an off-patent inhaled steroid and could be used to prevent the risk of people getting seriously ill with the disease, if taken within the first week of developing symptoms.
pharmaphorum
FEBRUARY 10, 2021
The pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival in patients with non-small cell lung cancer (NSCLC), sending the biotech’s share price skywards. . Interim data from a phase 2 trial of Heat’s off-the-shelf cell therapy with Opdivo (nivolumab) showed that patients treated with the duo as a second-line therapy had a survival benefit, particularly in patients who hadn’t previously had checkpoint inhibitor therap
pharmaphorum
FEBRUARY 9, 2021
Launching a rare disease patient registry often requires patient advocacy groups to design a registry themselves or pay for an expensive customized solution. With the launch of Rare Central , Pulse Infoframe offers patient advocacy groups an on-ramp to collecting real-world data, including natural history data, disease-specific data, and patient-reported outcomes.
pharmaphorum
FEBRUARY 9, 2021
The European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment for people with HIV that has developed resistance to other antiretroviral therapy (ART). . The first-in-class HIV attachment inhibitor is cleared for use as an add-on therapy to other ARTs in adults “for whom it is otherwise not possible to construct a suppressive antiviral regimen,” according to ViiV, which is majority-owned by GlaxoSmithKline.
pharmaphorum
FEBRUARY 10, 2021
MEDSIR , a global company dedicated to independent clinical research in oncology, has initiated the PHERGain II clinical trial to demonstrate that in patients with HER2-positive early breast cancer with a good prognosis, a chemotherapy-free therapeutic approach can be as effective as the current standard of care, which involves the use of this generally more toxic treatment.
pharmaphorum
FEBRUARY 10, 2021
Harness the Maternal-Infant Microbiome, Establish New Mechanisms of Action, and Develop Breakthrough Health Products that Proactively Prevent Disease Risk. Returning for another year, the 3rd Microbiome Movement – Maternal & Infant Health Summit will unite industry and academics in the exploration of preventative and therapeutic treatment of the microbiome during pregnancy and early life.
pharmaphorum
FEBRUARY 8, 2021
China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public. This is the second vaccine approved by China’s National Medical Products Administration (NMPA). Both of the vaccines, along with another experimental vaccine from Sinopharm, have been used in China’s vaccination programme. More than 31 million doses have been administered, mainly targeting groups at higher infection risks, while a fourth experimental vaccine from CanSino Biologics has been g
pharmaphorum
FEBRUARY 11, 2021
AstraZeneca is aiming to get a next-generation vaccine targeting emerging variants approved and into the arms of patients by the autumn, company representatives said in a press conference. Mene Pangalos, executive vice president of BioPharmaceuticals R&D, said work has already begun to tweak the shot developed with Oxford University to combat the new variants, which could be in the arms of patients by autumn.
pharmaphorum
FEBRUARY 10, 2021
A new EU-funded project called In Silico World aims to encourage the use of simulation for drug and medical device development. The project is coordinated by the University of Bologna and funded by the European Union’s Horizon 2020 research and innovation programme that involves more than a dozen partner institutions, including Italian startup InSilicoTrials.
pharmaphorum
FEBRUARY 8, 2021
Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide following a draft rejection in England by NICE last month. There are a range of MS drugs on the market but Zeposia does not have the common unpleasant gastrointestinal side effects that can occur with Biogen’s Tecfidera.
Expert insights. Personalized for you.
133 
Let's personalize your content